Independently Tested by Fraunhofer IZI
VireXbuster demonstrated greater than 99.9% reduction of Bovine Coronavirus in an independent study conducted at the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Leipzig, Germany.
About the Study
The Fraunhofer IZI is one of Germany’s leading independent research institutes. The study was conducted by PD Dr. Sebastian Ulbert and Dr. Alexandra Rockstroh from the Department of Vaccines and Infection Models, under strict BSL-2 (Biosafety Level 2) laboratory conditions.
VireXbuster-coated and non-coated (reference) specimens were exposed to Bovine Coronavirus (Betacoronavirus 1) — a close relative of human coronaviruses — for 24 hours at room temperature. Virus concentration was then measured using the TCID₅₀ assay (Tissue Culture Infection Dose 50), the gold standard for quantifying viral infectivity.
Key Results
>99.9%
Virus reduction
After 24 hours of surface contact
3.96 log
Titer reduction
Measured by TCID₅₀ assay
BSL-2
Lab standard
Fraunhofer IZI, Leipzig
Methodology
- Test organism: Betacoronavirus 1 / Bovine Coronavirus (sourced from Charité, Berlin)
- Two independent experiments with two replicates each
- 24-hour incubation at room temperature, protected from light
- Viral titer measured by TCID₅₀ assay on PT-cells (CCLV-RIE11)
- Conducted at Fraunhofer IZI, Leipzig — report dated 16 August 2021
Download the Full Report
Access the complete scientific report issued by Fraunhofer IZI, including methodology, raw data, and conclusions.
VireXbuster is certified as a Supplemental Residual Antimicrobial Product. It is not registered as a disinfectant under EPA regulations but is BauA-approved (Germany) and independently tested by Fraunhofer IZI, QualityLabs BT GmbH, and Dermatest GmbH.
See also: QualityLabs ISO 22196 Antibacterial | Dermatest Excellent Rating | Shop VireXbuster
